Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 7641 - 7648 of 12086 results

The Cyber President? What To Expect From the Trump Administration On Cybersecurity And Privacy
November 17, 2016| Blog| Viewpoint

New Balance caught up in Trump controversy
November 17, 2016| News

Pop goes the regulation
November 17, 2016| News

Arbitration Agreements — Incorporation by Reference of an Arbitration Clause in Another Document Is a Simple Matter ... Isn't It?
November 17, 2016| Article| Viewpoint

Mintz Attorney Douglas Hauer to Speak at NASAA 2016 Corporation Finance Training
November 16, 2016| Blog| Viewpoint

Transitioning the ACA: Republicans Must Avoid Disruption
November 16, 2016| Blog| Viewpoint

California AG Guidance for the Ed Tech Industry: 6 Recommendations to Protect Student Data Privacy
November 16, 2016| Blog| Viewpoint

2017 OIG Work Plan: For Medicare Plans
November 16, 2016| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts

Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|

Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
